The sweeping changes introduced by new BioMarin chief executive Alexander Hardy continue apace, with a second round of layoffs that will cut another 225 positions from its total headcount.
Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for startin
Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales, but lower profits for the second quarter.
A proposal by 23andMe founder and chief executive Anne Wojcicki to take the genetic testing company private has been rejected by a special committee of the board of directors.
GSK posted a healthy 13% increase in second-quarter sales this morning and raised its forecasts for the year on the back of gains for its cancer and HIV drugs, beating market expectations.
AstraZeneca, Roche, and Sanofi released their second-quarter results today, with a common theme – strong sales growth that caused them to raise their financial guidance for the year.